{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Perform spirometry', '-', 'Spirometry will be performed at approximately the same time of last visit after a wash', 'out period of bronchodilators according to their action duration, for example,', 'withholding the last dose of salbutamol/albuterol or levosalbutamol/levalbuterol for at', 'least 6 hours, withholding the last dose of LABA for at least 12 hours, and withholding', 'the last dose of LAMA for at least 24 hours. This will be verified before performing', 'the PEF measurements.', 'Assess menstruation status and perform urine dipstick pregnancy test for female patients', 'of childbearing potential (who have commenced menstruating)', 'Download electronic diary/PEF meter and remind patient to bring the device to the next', 'visit', 'Call IVRS/IWRS to register visit and obtain treatment kit number', 'Dispense and administer IMP', '-', 'Patients will be monitored at the study site for a minimum of 30 minutes after the', 'injection.', '-', 'Dispense Home Dosing Diary parent(s)/caregiver(s)/legal guardian(s) willing and', 'trained to perform home-administration of IMP-injection, and provide instructions on', 'preparation, injection and dose. And review the diary for home dosing. Re-check the', 'instructions on home-administration and dosing and dispense Home Dosing Diary, as', 'applicable.', '-', 'For parent(s)/caregiver(s)/legal guardian(s) unable or unwilling to administer IMP:', 'Arrangements must be made for the patient to receive IMP injections at the study site', 'as unscheduled visits, or for qualified site personnel and/or a professional caregiver to', 'administer IMP at home at q2w intervals.', 'Remind parent(s)/caregiver(s)/legal guardian(s) to use salbutamol/albuterol or', 'levosalbutamol/levalbuterol as reliever medication throughout the study. Instruct them to', 'record usage in the electronic diary.', 'Remind parent(s)/caregiver(s)/legal guardian(s) to continue their stable dose of ICS in', 'combination with a second controller as used during the Screening Period and instruct', 'them to record daily usage in the electronic diary.', 'Remind parent(s)/caregiver(s)/legal guardian(s) to withhold bronchodilators according to', 'their action duration, for example, withholding the last dose of salbutamol/albuterol or', 'levosalbutamol/levalbuterol for at least 6 hours, withholding the last dose of LABA for at', 'least 12 hours, and withholding the last dose of LAMA for at least 24 hours. This will be', 'verified before performing the PEF measurements.', 'Schedule a site visit 4 weeks later ( 3 days) and ask patient to come in at approximately', 'the same time of this visit', 'Property of the Sanofi Group - strictly confidential', 'Page 90', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '10.1.11', 'Visit 14 (Week 24 [+ 3 days])', 'Check compliance to IMP; record all concomitant medication use; inquire about', 'AEs/SAEs and background asthma therapy tolerability', 'Measure vital signs (blood pressure, heart rate, respiratory rate, body temperature, weight,', 'and height)', 'Perform physical examination', 'Urinalysis', 'Assess menstruation status and perform urine dipstick pregnancy test for female patients', 'of childbearing potential (who have commenced menstruating)', 'Administer ACQ-7', 'Administer all additional PROs:', 'PAQLQ(S)-IA, PRQLQ-IA, and PACQLQ :', 'EQ-5D-Y for children.', 'Administer HCRU', 'Measure exhaled nitric oxide', '-', 'Exhaled nitric oxide assessment is conducted prior to spirometry and following a fast', 'of > hour.', 'Perform spirometry', '-', 'Spirometry will be performed at approximately the same time of last visit after a wash', 'out period of bronchodilators according to their action duration, for example,', 'withholding the last dose of salbutamol/albuterol or levosalbutamol/levalbuterol for at', 'least 6 hours, withholding the last dose of LABA for at least 12 hours, and withholding', 'the last dose of LAMA for at least 24 hours. This will be verified before performing', 'the PEF measurements.', '-', 'Post-bronchodilator FEV1 should be determined.', 'Download electronic diary/PEF meter and remind patient to bring the device to the next', 'visit', 'Perform blood sampling for the following tests:', '-', 'Clinical laboratory testing ((hematology/biochemistry)', '-', 'Serum immunoglobulins (total IgG, IgG subclasses, IgM and IgA)', '-', 'Systemic drug concentration,', '-', 'ADAs', '-', 'Biomarker set, total IgE, and antigen-specific IgE, and antigen-specific IgG4 panel.', 'I', '-', 'Blood samples for pre-vaccination antibody titers for the patient(s) scheduled to', 'receive vaccination (ie, any tetanus, diphtheria, pertussis and/or seasonal', 'Property of the Sanofi Group - strictly confidential', 'Page 91', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}